A NOVEL APPROACH

Sanaregen™ Vision Therapeutics has a novel approach for developing regenerative therapies that  have the best chance of helping patients reclaim their lives. To that end, our 2024-2027 vision pipeline targets drusen-related retinal diseases, including hereditary diseases like Familial Drusen and Retinitis Pigmentosa, as well as degenerative retinal diseases related to aging such as Age-Related Macular Degeneration and Geographic Atrophy.